At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
magnesium oxide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Phase II Trial of Magnesium Supplements to Reduce Menopausal Hot Flashes in Cancer Patients
In Brief
A Phase 2 clinical trial evaluating magnesium oxide, questionnaire administration, and 1 other intervention for Breast Cancer and 3 related conditions. Completed, enrolled 31 participants.
Detailed Summary
RATIONALE: Magnesium oxide may help relieve hot flashes in women with cancer. PURPOSE: This phase II trial is studying how well magnesium oxide works in treating hot flashes in menopausal women with cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Cancer Survivor, Hot Flashes, Unspecified Adult Solid Tumor, Protocol Specific
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedNov 2009
Primary CompletionJan 2013
Study CompletionMar 2013
TodayJul 2026
First PostedNov 6, 2009
Enrollment StartJul 1, 2009
Primary CompletionJan 1, 2013
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 16.7 years ago
Interventions
magnesium oxidedrug
Given PO
questionnaire administrationother
Ancillary studies
quality-of-life assessmentprocedure
Ancillary studies